Cargando…
Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis
Bedaquiline (BDQ) has shown great value in the treatment of multidrug‐resistant tuberculosis (MDR‐TB) in recent years. However, exposure–safety relationships must be explored to extend the use of BDQ. Two reported safety findings for BDQ are prolongation of the QTc interval and elevation of transami...
Autores principales: | Tanneau, Lénaïg, Svensson, Elin M., Rossenu, Stefaan, Karlsson, Mats O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674006/ https://www.ncbi.nlm.nih.gov/pubmed/34626526 http://dx.doi.org/10.1002/psp4.12722 |
Ejemplares similares
-
Understanding the drug exposure–response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug‐resistant tuberculosis
por: Tanneau, Lénaïg, et al.
Publicado: (2020) -
Corrigendum to: Exposure‐safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis
Publicado: (2023) -
Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens
por: Tanneau, Lénaïg, et al.
Publicado: (2022) -
Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
por: Tanneau, Lénaïg, et al.
Publicado: (2022) -
Modelling of mycobacterial load reveals bedaquiline’s exposure–response relationship in patients with drug-resistant TB
por: Svensson, Elin M, et al.
Publicado: (2017)